FDA approves immunotherapy after surgery for stage III dMMR colon cancer
FDA approved atezolizumab with chemotherapy for stage III mismatch repair-deficient colon cancer after surgery; the supporting trial improved disease-free survival but increased severe adverse events.
The October 8 approval makes an existing trial result available under a new U.S. indication: atezolizumab added to fluoropyrimidine/oxaliplatin chemotherapy after surgery for stage III mismatch repair-deficient, or dMMR, colon cancer.
This is a defined tumor subgroup, not an indication for every colon-cancer patient. Eligibility also differs between intravenous and subcutaneous formulations. [1]
In ATOMIC, 355 participants were assigned to the added immunotherapy and 357 to chemotherapy alone. At median follow-up of 40.9 months, estimated three-year disease-free survival was 86.3% versus 76.2%—an absolute difference of 10.1 percentage points. Disease-free survival tracks recurrence or death; the result is not a measured 10.1-point gain in overall survival or a guarantee of cure. [2][3]
The benefit came with more toxicity. Grade 3 or 4 adverse events occurred in 84.1% versus 71.9% of treated patients. Those safety populations differ from the randomized efficacy groups. For a patient with this diagnosis, the useful conversation concerns the pathology’s mismatch-repair result, the expected absolute benefit and the added treatment burden. Individual costs and coverage were not checked. [2][3]
Sources & details 3 sources
Discuss in your voice app
Take the reporting, visual explanations and original sources into a conversation. Copy the brief, paste it into your preferred assistant, then start its voice mode.
Paste the brief into your voice app to discuss this reporting.Revised 9 October 2026. Copy edited 9 October to remove commentary about graphic design; reported claims, qualifications and source dates preserved.
Reporting sources
- FDA · October 8 approval and formulation eligibility
Original regulatory notice reopened after the barrier; approved setting, age/weight criteria, 711-adult/one-pediatric population and immune-mediated safety warnings checked.
- Sinicrope et al. · ATOMIC, NEJM March 26, 2026
Original trial abstract retrieved on PubMed: allocation, 40.9-month follow-up, three-year disease-free survival and grade 3/4 adverse events. Older evidence supports the new approval; no new trial publication is implied.
- OncLive · October 8, trial and safety analysis
Chris Ryan’s specialist report distinguishes overall survival from disease-free survival and gives treated safety denominators 346/334. It analyses the same trial, not a separate replication; full NEJM text was not retrieved.
Images & figures
Red PD-1 binds blue PD-L1 (left) or PD-L2 (right). David Goodsell, December 2016. Molecular context; this does not depict atezolizumab or an ATOMIC trial result.
David S. Goodsell / RCSB Protein Data Bank · Source · CC BY 4.0
Intervals show 95% confidence bounds for disease-free survival; the separate severe-event comparison shows incidence.
Euangelion · original explanatory graphic · Source · Usage terms · Download figure